Difference between revisions of "Asparaginase Erwinia chrysanthemi (Erwinaze)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>")
(updated content)
Line 3: Line 3:
 
==General information==
 
==General information==
 
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
 
Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.<ref name="insert">[http://www.erwinaze.com/pdf/PI_18-Nov2011.pdf Asparaginase Erwinia chrysanthemi (Erwinaze) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/asparaginaseerwinia.pdf Asparaginase Erwinia chrysanthemi (Erwinaze) package insert (locally hosted backup)]</ref>
+
aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.<ref name="insert">[http://www.erwinaze.com/pdf/PI_18-Nov2011.pdf Asparaginase Erwinia chrysanthemi (Erwinaze) package insert]</ref><ref>[[Media:Asparaginaseerwinia.pdf | Asparaginase Erwinia chrysanthemi (Erwinaze) package insert (locally hosted backup)]]</ref><ref>[http://www.erwinaze.com Erwinaze manufacturer's website]</ref>
 
<br>Route: IM
 
<br>Route: IM
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
Line 10: Line 10:
  
 
==Patient drug information==
 
==Patient drug information==
*[http://chemocare.com/bio/asparaginase.asp Asparaginase patient drug information (Chemocare)] -- note: this is for Asparaginase (Elspar), not Erwinaze<ref>[http://chemocare.com/bio/asparaginaseerwinia.asp Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (Chemocare)]</ref>
+
*[http://chemocare.com/chemotherapy/drug-info/erwinia-l-asparaginase.aspx Asparaginase patient drug information (Chemocare)] this is for Asparaginase (Elspar), not Erwinaze<ref>[http://chemocare.com/chemotherapy/drug-info/erwinia-l-asparaginase.aspx Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (Chemocare)]</ref>
 +
*Brief patient counseling information can be found on [http://www.erwinaze.com/pdf/PI_18-Nov2011.pdf#page=2 the bottom of page 2 of the package insert]<ref name="insert"></ref>
 
*[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/erwinia-asparaginase-patient-drug-information Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 15:39, 7 October 2012

FDA approved 11/18/2011

General information

Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2][3]
Route: IM
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References